menu
    • menu

    Company profile for Immatics

    NEW Drugs in Dev: 12
    Coral

    Virtual Booth

    Contact Supplier

    China’s top API & intermediate manufacturer, delivering advanced CMO/CDMO solutions to 60+ countries, empowering global health progress

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Alchem offers Botanical APIs for Pharmaceuticals, Cosmetics and Nutraceuticals// FDA-inspected and EU-GMP certified.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Immatics is a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting immunotherapies for the treatment of cancer. Our transformative product candidates are - best in class - Adoptive Cell Therapies and TCR Bispecific molecules TCER™. These products are directed against tumor targets that have been identified and validated by Immatics' proprietary and world-leading XPRESIDENT...
    Immatics is a clinical-stage biopharmaceutical company active in the discovery and development of T-cell redirecting immunotherapies for the treatment of cancer. Our transformative product candidates are - best in class - Adoptive Cell Therapies and TCR Bispecific molecules TCER™. These products are directed against tumor targets that have been identified and validated by Immatics' proprietary and world-leading XPRESIDENT® technology. Our mission is to deliver the power of T-cell redirecting immunotherapies to cancer patients.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    ImmaticsGermany Flag
    Country
    Country
    Germany
    Address
    Address
    Paul-Ehrlich-Str. 15 72076 Tuebingen Germany
    Telephone
    Telephone
    +49 (7071) 5397-0
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://immatics.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/immatics-biotechnologies/?originalSubdomain=de
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/immatics

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Immatics Showcases Anzu-Cel PRAME Cell Therapy Results At 2026
    Immatics Showcases Anzu-Cel PRAME Cell Therapy Results At 2026

    01 Jun 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/06/01/3304266/0/en/immatics-presents-clinical-activity-and-response-dynamics-of-anzu-cel-prame-cell-therapy-at-2026-asco-annual-meeting.html

    GLOBENEWSWIRE
    01 Jun 2026
    Share Share
    Immatics IMA401 Bispecific Data at ASCO, Published in Nature
    Immatics IMA401 Bispecific Data at ASCO, Published in Nature

    31 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/31/3303923/0/en/immatics-presents-data-on-ima401-magea4-8-bispecific-at-2026-asco-annual-meeting-with-simultaneous-publication-in-nature-medicine-supporting-development-of-ima401-ima402-combinatio.html

    GLOBENEWSWIRE
    31 May 2026
    Share Share
    Immatics' IMA203CD8 PRAME Therapy Data in Gynecologic Cancers
    Immatics' IMA203CD8 PRAME Therapy Data in Gynecologic Cancers

    30 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/30/3303876/0/en/immatics-presents-clinical-activity-of-ima203cd8-prame-cell-therapy-in-hard-to-treat-gynecologic-cancers-at-2026-asco-annual-meeting.html

    GLOBENEWSWIRE
    30 May 2026
    Share Share
    Immatics Announces 4 Oral Sessions in Cell Therapy at 2026 ASCO
    Immatics Announces 4 Oral Sessions in Cell Therapy at 2026 ASCO

    21 Apr 2026

    // FIRSTWORD PHARMA

    https://firstwordpharma.com/story/7197383

    FIRSTWORD PHARMA
    21 Apr 2026
    Share Share
    Immatics' TCR Achieves Remission in Children with Nephroblastoma
    Immatics' TCR Achieves Remission in Children with Nephroblastoma

    19 Apr 2026

    // FIRSTWORD PHARMA

    https://firstwordpharma.com/story/7187983

    FIRSTWORD PHARMA
    19 Apr 2026
    Share Share
    Immatics Reveals 2025 Financials And Business Progress
    Immatics Reveals 2025 Financials And Business Progress

    05 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/05/3250021/0/en/Immatics-Announces-Full-Year-2025-Financial-Results-and-Business-Update.html

    GLOBENEWSWIRE
    05 Mar 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search